Literature DB >> 23768063

NVP-BEZ235, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, prominently enhances radiosensitivity of prostate cancer cell line PC-3.

Wenjie Zhu1, Weijiang Fu, Likuan Hu.   

Abstract

BACKGROUND: Aberrant activation of phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway may account for development of radioadaptation and is not rare in prostate cancer. Neither PI3K nor mTOR blockade could completely inhibit the pathway owing to paradoxical feedback, so we anticipate dual PI3K/mTOR blockade by NVP-BEZ235 to radiosensitize prostate cancer cells.
METHODS: We investigated into the radiosensitizing effect of NVP-BEZ235 on PC-3 cells, which are devoid of androgen receptors. Clonogenic survival and MTT assays were performed, and to pursue underlying cellular changes flow cytometric analysis of cell cycle and apoptosis as well as western blot were carried out.
RESULTS: Exposure to NVP-BEZ235 and irradiation caused a greater degree of survival inhibition than ionizing radiation (IR) or BEZ235 alone. Dual PI3K/mTOR blockade along with IR induced a G2/M arrest and enhanced proapoptotic effect. NVP-BEZ235 radiosensitized PC-3 cells through counteracting constitutive as well as IR-triggered activation of Akt/mTOR signaling.
CONCLUSIONS: Our study demonstrated that the dual PI3K/mTOR inhibitor NVP-BEZ235 prominently improved the radiosensitivity of PC-3 cells. It sensitized tumor cells to irradiation via interruption of cell cycle progression and augmentation of cell apoptosis, which was due to its constraint on constitutive and IR-elicited PI3K/Akt/mTOR signaling activation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23768063     DOI: 10.1089/cbr.2012.1443

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  10 in total

1.  Survival and prognosis analyses of concurrent PIK3CA mutations in EGFR mutant non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.

Authors:  Xiaotong Qiu; Yong Wang; Fen Liu; Lihong Peng; Chen Fang; Xiaoyin Qian; Xinwei Zhang; Qian Wang; Zhehao Xiao; Renfang Chen; Shangkun Yuan; Yong Li
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

2.  Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway.

Authors:  Lili Song; Shikai Liu; Sufen Zhao
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

3.  Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions.

Authors:  Sebastian Kuger; Emre Cörek; Bülent Polat; Ulrike Kämmerer; Michael Flentje; Cholpon S Djuzenova
Journal:  Breast Cancer (Auckl)       Date:  2014-03-16

Review 4.  Cancer stem cells and signaling pathways in radioresistance.

Authors:  Lei Chang; Peter Graham; Jingli Hao; Jie Ni; Junli Deng; Joseph Bucci; David Malouf; David Gillatt; Yong Li
Journal:  Oncotarget       Date:  2016-03-08

5.  Combined treatment of pancreatic cancer xenograft with 90Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor.

Authors:  Winn Aung; Atsushi B Tsuji; Hitomi Sudo; Aya Sugyo; Yoshinori Ukai; Katsushi Kouda; Yoshikazu Kurosawa; Takako Furukawa; Tsuneo Saga; Tatsuya Higashi
Journal:  World J Gastroenterol       Date:  2017-11-14       Impact factor: 5.742

Review 6.  Targeting PI3K in cancer: mechanisms and advances in clinical trials.

Authors:  Jing Yang; Ji Nie; Xuelei Ma; Yuquan Wei; Yong Peng; Xiawei Wei
Journal:  Mol Cancer       Date:  2019-02-19       Impact factor: 27.401

Review 7.  Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors.

Authors:  Kasun Wanigasooriya; Robert Tyler; Joao D Barros-Silva; Yashashwi Sinha; Tariq Ismail; Andrew D Beggs
Journal:  Cancers (Basel)       Date:  2020-05-18       Impact factor: 6.639

Review 8.  Inhibiting Cytoprotective Autophagy in Cancer Therapy: An Update on Pharmacological Small-Molecule Compounds.

Authors:  Lijuan Zhang; Yuxuan Zhu; Jiahui Zhang; Lan Zhang; Lu Chen
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

Review 9.  Radiation oncology in vitro: trends to improve radiotherapy through molecular targets.

Authors:  Natália Feofanova; Jony Marques Geraldo; Lídia Maria de Andrade
Journal:  Biomed Res Int       Date:  2014-09-15       Impact factor: 3.411

10.  Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.

Authors:  Sebastian Kuger; Michael Flentje; Cholpon S Djuzenova
Journal:  Radiat Oncol       Date:  2015-10-24       Impact factor: 3.481

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.